Genomic Vision’s Technology is Acquired by Department of Cell Biology, Microbiology & Molecular Biology at the University of South Florida to Study Mechanisms of DNA Replication and Replication Stress
17 Février 2022 - 6:00PM
Business Wire
Regulatory News:
Genomic Vision (the “Company” - FR0011799907 – GV)
(Paris:GV), a biotechnology company that develops tools and
services dedicated to the analysis and control of changes in the
genome, today announced that University of South Florida is
implementing the full Molecular Combing workflow using FiberComb,
FiberVision S and FiberStudio solutions.
Researchers at University of South Florida received National
Institute for Health (NIH) funding to acquire Genomic Vision
technology to implement the company’s replication combing assay
workflows with an outlook to study more than 100 samples in the
first year of the grant award using Molecular Combing.
Genomic Vision’s replication combing assay provides a clear read
out of spatial and temporal characteristics of DNA replication that
enables the characterization of universal and targeted genomic
replication events providing researchers with critical DNA
replication features such as initiation rate, replication fork
velocity and replication fork progression.
In cancer studies, these features of DNA replication help in
drug development because Molecular Combing allows a clear view of
mechanistic understandings of genomic instabilities.
“Obtaining a better understanding of the mechanisms that
maintain the stability of the human genome, including those that
function at the interface between DNA replication, recombination
and repair, is a very important part of our program with the NIH,
especially as it relates to the Bloom syndrome DNA helicase and its
interacting factors,” said Professor Kristina Schmidt, Professor
of Cell & Molecular Biology at the University of South
Florida. “Adding Molecular Combing to our laboratory expertise
will help us expand our research on how DNA damage, unusual DNA
structures, and changes in replisome composition affect DNA
replication and give rise to genome instability and increased
cancer risk”.
“Errors in DNA replication are the leading cause for mutagenesis
and genome instability. Characterizing the mechanisms that control
replication dynamics and fork stability in response to replication
stress is the major focus of our NIH-aided program, and acquisition
of this combing technology provides a whole new dimension to our
research efforts” said Huzefa Dungrawala, Assistant Professor of
Cell & Molecular Biology at the University of South
Florida.
“The DNA replication analysis segment is a leading application
for our Molecular Combing technology, enabling the research and
biotechnology clients to obtain a clear read out of spatial and
temporal characteristics of DNA replication.” said Dominique
Remy-Renou, CEO of Genomic Vision. “We are thrilled to partner
with University of South Florida to provide novel insights for
structural variation and genomic rearrangement analysis in complex
genetic disease research and drug development studies.”
***
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Genomic Vision, based near Paris in Bagneux, is a
public listed company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
***
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on February 9, 2021 under
reference number R.21-002, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220217005749/en/
Genomic Vision Dominique Remy-Renou CEO Tel.: +33 1 49 08
07 51 investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
Tel.: +33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024